Search Results - "Katelaris, P."

Refine Results
  1. 1

    Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis by Lunney, P. C., Kariyawasam, V. C., Wang, R. R., Middleton, K. L., Huang, T., Selinger, C. P., Andrews, J. M., Katelaris, P. H., Leong, R. W. L.

    Published in Alimentary pharmacology & therapeutics (01-07-2015)
    “…Summary Background Smoking demonstrates divergent effects in Crohn's disease (CD) and ulcerative colitis (UC). Smoking frequency is greater in CD and…”
    Get full text
    Journal Article
  2. 2
  3. 3

    The effectiveness of rifabutin triple therapy for patients with difficult‐to‐eradicate Helicobacter pylori in clinical practice by VAN DER POORTEN, D., KATELARIS, P. H.

    Published in Alimentary Pharmacology and Therapeutics (01-12-2007)
    “…Summary Background  Failure of first line and subsequent Helicobacter pylori eradication therapy is a significant problem and alternative treatments are few…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Patients' knowledge of pregnancy-related issues in inflammatory bowel disease and validation of a novel assessment tool ('CCPKnow') by Selinger, C. P., Eaden, J., Selby, W., Jones, D. B., Katelaris, P., Chapman, G., McDonald, C., McLaughlin, J., Leong, R. W. L., Lal, S.

    Published in Alimentary pharmacology & therapeutics (01-07-2012)
    “…Summary Background Inflammatory bowel diseases (IBD) require complex therapeutic decisions and life choices concerning pregnancy, but little is known about…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study by Labenz, J., Armstrong, D., Lauritsen, K., Katelaris, P., Schmidt, S., Schütze, K., Wallner, G., Juergens, H., Preiksaitis, H., Keeling, N., Nauclér, E., Eklund, S.

    Published in Alimentary pharmacology & therapeutics (15-03-2005)
    “…Summary Aim:  To assess the efficacy of the 8‐week therapy with esomeprazole 40 mg vs. pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a…”
    Get full text
    Journal Article
  10. 10

    Clinical trial: the treatment of gastro‐oesophageal reflux disease in primary care – prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg by EGGLESTON, A., KATELARIS, P. H., NANDURKAR, S., THORPE, P., HOLTMANN, G.

    Published in Alimentary pharmacology & therapeutics (01-05-2009)
    “…Summary Background  A trial of empirical PPI therapy is usual practice for most patients with symptoms of gastro‐oesophageal reflux disease (GERD) in primary…”
    Get full text
    Journal Article
  11. 11

    Who needs colonoscopy to identify colorectal cancer? Bowel symptoms do not add substantially to age and other medical history by Adelstein, B.‐A., Irwig, L., Macaskill, P., Turner, R. M., Chan, S. F., Katelaris, P. H.

    Published in Alimentary pharmacology & therapeutics (01-07-2010)
    “…Aliment Pharmacol Ther 2010; 32: 270–281 Summary Background  Many bodies advise that people with bowel symptoms undergo colonoscopy to detect colorectal…”
    Get full text
    Journal Article
  12. 12

    An objective study of acid reflux and cough in children using an ambulatory pHmetry–cough logger by Chang, A B, Connor, F L, Petsky, H L, Eastburn, M M, Lewindon, P J, Hall, C, Wilson, S J, Katelaris, P H

    Published in Archives of disease in childhood (01-05-2011)
    “…Objective There are no objective ambulatory studies on the temporal relationship between reflux and cough in children. Commercial pHmetry loggers have slow…”
    Get full text
    Journal Article
  13. 13

    Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis : results from the EXPO study by LABENZ, J, ARMSTRONG, D, NAUCLER, E, ADLER, J, EKLUND, S, LAURITSEN, K, KATELARIS, P, SCHMIDT, S, SCHÜTZE, K, WALLNER, G, JUERGENS, H, PREIKSAITIS, H, KEELING, N

    Published in Alimentary pharmacology & therapeutics (01-11-2005)
    “…Following initial healing of erosive oesophagitis, most patients require maintenance therapy to prevent relapse. To compare endoscopic and symptomatic…”
    Get full text
    Journal Article
  14. 14

    The relation between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the human stomach by Zhang, Z W, Patchett, S E, Perrett, D, Katelaris, P H, Domizio, P, Farthing, M J G

    Published in Gut (01-09-1998)
    “…Background—Vitamin C may be protective against gastric cancer though infection withHelicobacter pylori is associated with a reduction in intragastric…”
    Get full text
    Journal Article
  15. 15

    Review article: oesophageal complications and consequences of persistent gastro‐oesophageal reflux disease by Pisegna, J., Holtmann, G., Howden, C. W., Katelaris, P. H., Sharma, P., Spechler, S, Triadafilopoulos, G., Tytgat, G.

    Published in Alimentary pharmacology & therapeutics (01-12-2004)
    “…Summary The major oesophageal complications associated with persistent gastro‐oesophageal reflux disease (GERD) include erosive oesophagitis, ulceration,…”
    Get full text
    Journal Article
  16. 16

    Aspartate aminotransferase : alanine aminotransferase ratio in chronic hepatitis C infection: Is it a useful predictor of cirrhosis? by Park, Gordon J-H, Lin, Betty Pc, Ngu, Meng C, Jones, D Brian, Katelaris, Peter H

    Published in Journal of gastroenterology and hepatology (01-04-2000)
    “…Background : The clinical usefulness of the ratio of serum aspartate aminotransferase (AST) to alanine aminotransferase (ALT) has been explored in several…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men by Katelaris, P H, Seow, F, Lin, B P, Napoli, J, Ngu, M C, Jones, D B

    Published in Gut (01-08-1993)
    “…Gastric acid secretion has been considered to decline with increasing age but this view is being re-evaluated as the importance of Helicobacter pylori…”
    Get full text
    Journal Article
  19. 19

    The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy by Park, G J-H, Katelaris, P H, Jones, D B, Seow, F, Lin, B P C, Le Couteur, D G, Ngu, M C

    Published in Alimentary pharmacology & therapeutics (01-09-2005)
    “…The 13C-caffeine breath test is a non-invasive, quantitative test of liver function. To determine the utility of the 13C-caffeine breath test in chronic…”
    Get full text
    Journal Article
  20. 20

    Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study by KATELARIS, P. H, ADAMTHWAITE, D, MIDOLO, P, YEOMANS, N. D, DAVIDSON, G, LAMBERT, T

    Published in Alimentary pharmacology & therapeutics (01-06-2000)
    “…Background: The efficacy of omeprazole‐based eradication therapies has been determined mostly in populations with low to moderate prevalence of metronidazole…”
    Get full text
    Journal Article